PSMA-targeted PET/CT is not only used for the staging of prostate cancer, but it is also a useful tool for therapy monitoring [14, 15] and indispensable for verifying PSMA expression prior to PSMA-RLT [16]. This evidence concerns the gene FOLH1 and prostate carcinoma.